The eOD-GT8 60mer nanoparticle, a germline-targeting immunogen, reproducibly primes rare VRC01-class broadly neutralizing antibody (bnAb) precursor B cells in humans (IAVI G001, 97% of vaccinees), and X-ray structures of trial-elicited precursors show that they already engage the HIV-1 envelope CD4-binding site in the mature-bnAb binding mode. However, the immunogen lacks the dense glycan shield and trimeric context of native envelope, and primed precursors bind N276-glycan-bearing antigen ~58-fold more weakly. The open problem is whether these primed lineages can be driven through sequential heterologous booster immunizations in humans to accumulate the somatic hypermutation needed to accommodate fully glycosylated, trimeric Env — including the N276 glycan — and to achieve broad, potent neutralization of wild-type HIV-1 at the serum level. A 2025 first-boost trial (IAVI G002) demonstrated early maturation and neutralization of only N276-lacking pseudoviruses; no vaccine-elicited VRC01-class antibody has yet broadly neutralized wild-type virus in humans.

Background

HIV-1 entry is mediated by the envelope glycoprotein (Env), a trimer of gp120/gp41 heterodimers whose exposed surface is shielded by a dense layer of host-derived N-linked glycans. A minority of infected individuals eventually develop broadly neutralizing antibodies (bnAbs) — antibodies that neutralize a wide range of viral strains — several of which target the CD4-binding site (CD4bs), the conserved gp120 recess to which the CD4 receptor docks. The prototypical CD4bs bnAbs (VRC01 and relatives) form a 'class': they all use a heavy chain encoded by the IGHV1-2*02 gene, whose HCDR2 loop mimics CD4 by straddling the gp120 CD4-binding loop, paired with short (typically five-residue) light-chain CDR3s that avoid steric clashes with the V5 and D loops of gp120. These bnAbs carry very heavy somatic hypermutation (SHM) — the point mutations that a B cell accumulates in its antibody gene during affinity maturation in germinal centers — often 30–50% amino-acid divergence from germline, and part of that mutation load exists specifically to accommodate conserved CD4bs-proximal glycans, above all the N276 glycan in loop D, which sterically blocks the germline light chain (Kong et al. 2016 showed these glycans act as roadblocks in natural infection).

Germline targeting is a rational vaccine strategy built around this biology: a priming immunogen is engineered to bind the unmutated precursor B-cell receptor (BCR) of the desired bnAb class, however rare those naive B cells are; sequential heterologous booster immunogens ('shaping' then 'polishing' immunogens) are then meant to progressively introduce native Env features — the inner gp120 domain, neighboring protomers of the trimer, and native glycosylation — so that affinity maturation selects mutations that surmount each barrier in turn. The prototype prime is eOD-GT8, an engineered gp120 outer domain displayed on a self-assembling 60mer nanoparticle (Jardine et al. 2013). The IAVI G001 phase 1 trial showed that eOD-GT8 60mer in 97% of recipients expanded VRC01-class precursors with modest SHM (Leggat et al. 2022).

The source study (Lin et al. 2025, PNAS) solved X-ray structures of five trial-elicited VRC01-class precursor Fabs (using four different light-chain V genes) in complex with eOD-GT8. All five engage the CD4bs through the canonical HCDR2-dominated mode of mature VRC01-class bnAbs despite >90% germline identity, and two structures with an N276-bearing antigen reveal distinct germline-level mechanisms (LCDR1 repositioning or HCDR3 curvature) for accommodating the N276 glycan. Surface plasmon resonance (SPR) over 230 trial-derived monoclonal antibodies showed 87% retain detectable binding to N276-bearing eOD-GT8, but with a geometric mean ~58-fold weaker affinity (KDK_D reduced from the low-nanomolar range toward the hundreds-of-nanomolar range). The study's own discussion identifies what remains unresolved: the priming immunogen lacks the dense glycan shield, structural dynamics, and neighboring protomers of native-like trimers, so additional SHM is required to overcome the steric and electrostatic challenges of fully glycosylated trimeric Env — a process not yet demonstrated in humans — and the capacity of the primed precursors to undergo iterative affinity maturation through boosters, ultimately achieving broad neutralization, remained to be tested clinically. Related questions are whether binding at the observed N276-penalized affinity can ever translate into functional neutralization of native viral strains, and how far the five solved structures represent the full diversity of elicited precursors (e.g., across HCDR3 lengths and D-gene usage).

Problem Statement

Determine whether VRC01-class bnAb precursor lineages elicited in humans by the eOD-GT8 60mer germline-targeting immunogen (IAVI G001) can be matured by sequential heterologous booster immunizations into antibodies that broadly and potently neutralize wild-type HIV-1 — and, as required steps toward that endpoint: (i) establish which additional somatic hypermutation beyond the primed state (<10% amino-acid divergence, structures already bnAb-like) is needed for the lineages to overcome the steric and electrostatic barriers of fully glycosylated, trimeric Env, above all the N276 glycan and the surrounding CD4bs-proximate glycan shield, and whether those mutations can be elicited by vaccination in humans; and (ii) establish how affinity maturation can overcome the ~58-fold affinity penalty that primed precursors incur on N276-bearing antigen, to the point of functional neutralization of native HIV-1 strains (detectable neutralization being associated in clinical data with sub-500 nM binding and slow off-rates). An affirmative answer requires demonstrating, in vaccinated humans, VRC01-class serum antibody responses and/or memory-B-cell-derived monoclonal antibodies — traceable by BCR sequencing to the primed precursors — that neutralize a multiclade panel of wild-type (N276-containing) HIV-1 pseudoviruses at breadth and potency meeting accepted bnAb criteria (conventionally on the order of ≥50% breadth on standard tier-2 multiclade panels). A negative or inconclusive answer requires an evidence-based determination, judged against those same breadth and potency thresholds, that the primed lineages cannot (or, on the evidence available to date, cannot yet) be matured to that endpoint — for example because the requisite somatic mutations are not elicitable by vaccination in humans, or because the elicited antibodies remain below the breadth and potency criteria — with the governing evidence, or its absence, stated explicitly; a documented determination that the endpoint can or cannot be met at those thresholds resolves the task, whereas a proposed immunogen-boost design that does not adjudicate them does not. Sub-steps (i) and (ii) are independently refutable: resolving either establishes the corresponding component of the maturation pathway but does not, on its own, resolve the overall question. The problem spans immunogen design, the elicitation of specific mutation routes, and the functional readout because these are jointly the stated objective of the sequential germline-targeting strategy; no restriction to a particular delivery platform (protein, mRNA-LNP), trimer or core format, dose, or number of boosts is implied.

References

  1. Lin X, Cottrell CA, Kalyuzhniy O, Tingle R, Kubitz M, Lu D, Yuan M, Schief WR, Wilson IA. Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial. Proceedings of the National Academy of Sciences 122(33): e2510163122 (2025). doi:10.1073/pnas.2510163122, https://doi.org/10.1073/pnas.2510163122 (preprint doi:10.1101/2025.05.22.655646, https://doi.org/10.1101/2025.05.22.655646)
  2. Leggat DJ, Cohen KW, Willis JR, et al. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 378: eadd6502 (2022). doi:10.1126/science.add6502, https://doi.org/10.1126/science.add6502
  3. Willis JR, Prabhakaran M, Muthui M, et al. Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans. Science 389(6759): eadr8382 (2025). doi:10.1126/science.adr8382, https://doi.org/10.1126/science.adr8382
  4. Caniels TG, Prabhakaran M, Ozorowski G, et al. Precise targeting of HIV broadly neutralizing antibody precursors in humans. Science 389(6759): eadv5572 (2025). doi:10.1126/science.adv5572, https://doi.org/10.1126/science.adv5572
  5. Stamatatos L. The Germline Targeting Vaccine Concept: Overview and Updates from HIV Pre-Clinical and Clinical Trials. Current HIV Research 23(6): 380-390 (2026). doi:10.2174/011570162X358302250206074255, https://doi.org/10.2174/011570162X358302250206074255
  6. Mendes Silva C, Sanders RW, Caniels TG. Preclinical and clinical trials for vaccine induction of CD4-binding site-neutralizing antibodies. Current Opinion in HIV and AIDS (2026). doi:10.1097/coh.0000000000001065, https://doi.org/10.1097/coh.0000000000001065
  7. Jardine J, Julien J-P, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340(6133): 711-716 (2013). doi:10.1126/science.1234150, https://doi.org/10.1126/science.1234150
  8. Kong L, Ju B, Chen Y, et al. Key gp120 glycans pose roadblocks to the rapid development of VRC01-class antibodies in an HIV-1-infected Chinese donor. Immunity 44(4): 939-950 (2016). doi:10.1016/j.immuni.2016.03.006, https://doi.org/10.1016/j.immuni.2016.03.006
  9. Chen X, Zhou T, Schmidt SD, et al. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. Immunity 54(2): 324-339 (2021). doi:10.1016/j.immuni.2020.12.014, https://doi.org/10.1016/j.immuni.2020.12.014